PATENT CLAIM ANALYSIS

Application Number: 16054728
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["544", "343000"]

Abstract:
This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT 2A  receptor, serotonin transporter (SERT) and/or pathways involving dopamine D 1 /D 2  receptor signaling systems, and/or the treatment of residual symptoms.

Claim (Index 13):
The method according to  claim 12 , wherein said disorder is selected from a group consisting of obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, agitation, agitation in dementia, agitation in autism and related autistic disorders, gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility, post-traumatic stress disorder, impulse control disorders, and intermittent explosive disorder.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 96.0
- Lexical Diversity: 1.29091
- Patent Class: 544.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15301895', '16088397', '15301912', '14394467', '15629481']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8307677910395697
- 35 USC 102 Novelty (BERT): 0.5491370702522937
- Combined Prediction Score: 0.8026047189608421
- Mean Citation Score: 377.4376160000001
- Max Citation Score: 431.4497
- Similarity Product: 345.5402908044457

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test